Drugs / Copper Cu 64-DOTA-Trastuzumab
Copper Cu 64-DOTA-Trastuzumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05376878 | Dec 2022 → Apr 2027 expected | invasive breast carcinoma, metastatic malignant neoplasm in the brain | City of Hope Medical Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Copper Cu 64-DOTA-Trastuzumab | “Copper Cu 64-DOTA-Trastuzumab” NCT05376878 ↗ |
| Modality | Diagnostic / imaging agent | “64Cu-DOTA-trastuzumab positron emission tomography” NCT05376878 ↗ |
| Route | Intravenous | “Given IV” NCT05376878 ↗ |